regadenoson + Optimark®

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, CAD

Trial Timeline

May 16, 2014 → Oct 23, 2017

NCT ID

NCT01949844

About regadenoson + Optimark®

regadenoson + Optimark® is a pre-clinical stage product being developed by Astellas Pharma for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01949844. Target conditions include Coronary Artery Disease, CAD.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01949844	Pre-clinical	Completed	May 16, 2014	Oct 23, 2017	Coronary Artery Disease

Competing Products

20 competing products in Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40